STTR Phase I: Portable single cell cytology and predictive analysis platform for the early detection of epithelial cancers

STTR 第一期：用于上皮癌早期检测的便携式单细胞细胞学和预测分析平台

• 批准号: 2233372
• 负责人: Nicolaos Christodoulides
• 金额: $ 27.5万
• 依托单位: ORALIVA, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2233372&HistoricalAwards=false
• 关键词: STTR; Phase; Portable; single; cell

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project will address the need for an accessible method to identify early-stage epithelial cancers, with high accuracy, earlier and at lower cost than is currently available. In 2020, the total cost of cancer care was nearly $210 billion. Due to the nature of current cancer diagnostics, most cancers are diagnosed and treated during late-stages. This results in a large economic burden to patients, families, healthcare providers, and facilities. To advance the health and welfare of the public and reduce the nation’s healthcare burden, there is a need for cancer screening, diagnostic, and monitoring devices that are non-invasive, cost-effective, easy-to-use, and accurate. The proposed platform for the early detection of multiple types of epithelial cancers 1) addresses the lack of effective non-invasive portable screening devices; 2) provides faster, more discriminatory assessments in near real-time; 3) yields the most precise and accurate results to identify cancers earlier, when interventions are more impactful, less expensive, less invasive, and more likely to improve patient outcomes.This Small Business Technology Transfer (STTR) Phase I project seeks to establish the feasibility of developing the first portable, programmable, single cell cytology platform for early detection of multiple types of epithelial cancers, suitable for use at the point-of-care. The proposed technology will uniquely combine microfluidics and artificial intelligence (AI) to act as a sensor and provide predictive analysis, allowing for the accurate classification of potentially cancerous tissue. The platform will support near real-time, multiparameter, single-cell cytology measurements and will provide a method for automated analysis of a plurality of key metrics. Proof of concept has been established for the application area of oral cavity cancers, with the approach demonstrating superior performance metrics compared to other diagnostics (tissue reflectance, tissue auto fluorescence, salivary testing, and cytology testing). It is the only adjunct that can distinguish between mild, moderate, and severe dysplasia. The key objectives for this project are to develop methodologies to link different clinical specimen types to the microfluidics environment, and a biomarker discovery process to identify biomarkers for different applications that are amenable to the platform. The successful completion of this project will enable the platform to recognize and assess various levels of dysplasia across multiple epithelial cancer types.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小型企业技术转移（STTR）I期项目的更广泛的影响/商业潜力将解决一种可访问方法的需求，以识别早期阶段上皮癌，其准确性很高，早于当前可用的成本较低。在2020年，癌症护理的总成本接近2100亿美元。由于当前癌症诊断的性质，大多数癌症在晚期被诊断和治疗。这会给患者，家庭，医疗保健提供者和设施带来巨大的经济燃烧。为了促进公众的健康和福利并减少国家的医疗保健烧伤，需要进行癌症筛查，诊断和监测设备，这些设备无创，具有成本效益，易于使用和准确。提出的早期检测到多种类型上皮癌的平台1）解决缺乏有效的非侵入性便携式筛选设备； 2）几乎实时提供更快，更具歧视性的评估； 3) yields the most precise and accurate results to identify cancers earlier, when interventions are more impactful, less expensive, less invasive, and more likely to improve patient outcomes.This Small Business Technology Transfer (STTR) Phase I project seeks to establish the feasibility of developing the first portable, programmable, single cell cytology platform for early detection of multiple types of epithelial cancers, suitable for use At the point-of-care.所提出的技术将唯一结合微流体和人工智能（AI）作为传感器并提供预测分析，从而可以准确地分类潜在的取消组织。该平台将支持接近实时的多参数，单细胞细胞学测量值，并将提供一种自动分析多个关键指标的方法。已经为口腔癌的应用领域建立了概念证明，与其他诊断相比（组织反射率，组织自动荧光，唾液测试和细胞学测试）相比，该方法表明性能指标卓越。它是唯一可以区分轻度，中度和严重发育不良的辅助手段。该项目的关键目标是开发方法，将不同的临床样本类型与微流体环境联系起来，以及一个生物标志物发现过程，以识别平台可调节的不同应用的生物标志物。该项目的成功完成将使平台能够识别和评估多种上皮癌类型中各种层次的发育不良。该奖项反映了NSF的法定任务，并使用基金会的知识分子和更广泛的影响评估审查标准，认为通过评估被认为是宝贵的支持。